Regeneron said that on a combined basis, EYLEA HD and EYLEA achieved $6 billion in aggregate U.S. net product sales for full-year 2024, representing 1% year-over-year growth, and aggregate U.S. net product sales for Q4 were $1.5 billion, based on preliminary (unaudited) results.

1. 01

   Regeneron said that on a combined basis, EYLEA HD and EYLEA achieved $6 billion in aggregate U.S. net product sales for full-year 2024, representing 1% year-over-year growth, and aggregate U.S. net product sales for Q4 were $1.5 billion, based on preliminary (unaudited) results.

2. 02

   The company said EYLEA HD U.S. net product sales were $305 million and EYLEA U.S. net product sales were $1.19 billion for Q4, and combined EYLEA HD and EYLEA U.S. net product sales for the period were favorably impacted by approximately $85 million as a result of higher wholesaler inventory levels for EYLEA, partially offset by lower wholesaler inventory levels for EYLEA HD.

3. 03

   Regeneron said it currently expects that its financial results calculated in accordance with GAAP and its non-GAAP financial results for Q4 2024 will include an acquired in-process research and development charge of approximately $14 million on a pre-tax basis, primarily relating to asset acquisitions, and this charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share by approximately $0.11.

4. 04

   Regeneron said Libtayo exceeded $1 billion in sales for 2024 and that adjuvant Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death compared to placebo in a Phase 3 study in high-risk cutaneous squamous cell carcinoma. The company plans to submit to the FDA in the first half of 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.